An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma.

@article{Kanai2014AnOP,
  title={An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma.},
  author={Fumihiko Kanai and Shuntaro Obi and Shigetoshi Fujiyama and Shuichiro Shiina and Hideyuki Tamai and Hitoshi Mochizuki and Yukihiro Koike and Jun Imamura and Takayoshi Yamaguchi and Isamu Saida and Osamu Yokosuka and Masao Omata},
  journal={Hepatology international},
  year={2014},
  volume={8 1},
  pages={94-103}
}
AIM Tamibarotene is a synthetic retinoid expected to inhibit tumor-cell proliferation and to induce apoptosis by selective interaction with retinoic acid receptor α/β. We conducted an open-label phase I/II study to determine the maximum tolerated dose (MTD) and recommended dose (RD), and to evaluate the pharmacokinetics, efficacy, and safety profiles for… CONTINUE READING